Mallinckrodt Beheer

Beheer criteriumcontroles 0/4

De CEO Mallinckrodt is Siggi Olafsson, benoemd in Jun2022, heeft een ambtstermijn van 1.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.97M, bestaande uit 8.2% salaris en 91.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.3% van de aandelen van het bedrijf, ter waarde $ 2.78K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 1.4 jaar.

Belangrijke informatie

Siggi Olafsson

Algemeen directeur

US$7.0m

Totale compensatie

Percentage CEO-salaris	8.2%
Dienstverband CEO	1.4yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	1.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Siggi Olafsson's beloning veranderd ten opzichte van Mallinckrodt's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 29 2023	n/a	n/a	-US$3b
Jun 30 2023	n/a	n/a	-US$2b
Mar 31 2023	n/a	n/a	-US$1b

Compensatie versus markt: De totale vergoeding ($USD 6.97M ) Siggi } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Siggi te vergelijken met de prestaties van het bedrijf.

CEO

Siggi Olafsson (54 yo)

1.4yrs

Tenure

US$6,965,770

Compensatie

Mr. Sigurdur Oli Olafsson, also known as Siggi, Ph D., serves as President and Chief Executive Officer and Director at Mallinckrodt plc since June 25, 2022. He had been an Executive officer since May 2022...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sigurdur Olafsson	CEO, President & Director	1.4yrs	US$6.97m	0.30% $ 2.8k
Bryan Reasons	Executive VP & CFO	4.7yrs	US$3.82m	0.16% $ 1.5k
Mark Tyndall	Executive VP	1.3yrs	US$3.96m	0.10% $ 961.9
Henriette Nielsen	Executive VP & Chief Transformation Officer	1.3yrs	US$2.46m	0.091% $ 855.9
Stephen Welch	Executive VP & Head of Specialty Generics	no data	US$2.24m	0.057% $ 536.0
Peter Richardson	Executive VP & Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
Kassie Harrold	Executive VP & Chief Compliance Officer	2.8yrs	geen gegevens	0.052% $ 487.9
Daniel Speciale	Senior VP of Finance & CFO of Specialty Generics	less than a year	geen gegevens	geen gegevens
Jason Goodson	Executive VP & Chief Strategy and Restructuring Officer	less than a year	geen gegevens	0.061% $ 567.2
Lisa French	Executive VP & Chief Commercial Officer	1.1yrs	geen gegevens	0.11% $ 1.0k
John Einwalter	VP & Treasurer	no data	geen gegevens	geen gegevens
David Keenan	VP of Global External Manufacturing & MD of Mallinckrodt Pharmaceuticals	9.8yrs	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MNKT.Q wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sigurdur Olafsson	CEO, President & Director	1.4yrs	US$6.97m	0.30% $ 2.8k
Paul Bisaro	Independent Chairman of the Board	1.4yrs	US$723.10k	0.0098% $ 91.7
James Sulat	Independent Director	1.4yrs	US$628.37k	0.30% $ 2.8k
Woodrow Myers	Independent Director	1.4yrs	US$611.28k	0.075% $ 698.9
John Vierling	Member of Scientific Advisory Council	no data	geen gegevens	geen gegevens
Neal Goldman	Independent Director	1.4yrs	US$626.74k	0.075% $ 698.9
Daniel Celentano	Independent Director	1.4yrs	US$615.92k	0.075% $ 698.9
Ulrich von Andrian-Werburg	Member of Scientific Advisory Council	5.4yrs	geen gegevens	geen gegevens
Karen Ling	Independent Director	1.3yrs	US$451.22k	0.075% $ 698.9
Riad El-Dada	Independent Director	1.4yrs	US$607.47k	0.075% $ 698.9
Jörg Gerlach	Member of Scientific Advisory Council	5.4yrs	geen gegevens	geen gegevens
Rashmin Savani	Member of Scientific Advisory Council	5.4yrs	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MNKT.Q wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw bestuur.

Mallinckrodt Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Mallinckrodt plc, Annual General Meeting, May 09, 2024

Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt plc Announces Appointment of Peter Richardson as Chief Scientific Officer

Mallinckrodt plc Appoints Karen L. Ling as Human Resources and Compensation Committee of the Board

Mallinckrodt plc Appoints Susan Silbermann to Its Board of Directors

Mallinckrodt plc Announces Appointment of Lisa French as Executive Vice President and Chief Commercial Officer, Effective October 1, 2022

Recent updates

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver (EASL) Congress

Mallinckrodt plc Reaffirms Financial Guidance for the Full Year of 2024

Mallinckrodt plc, Annual General Meeting, May 09, 2024

Mallinckrodt plc Provides Earnings Guidance for the Year 2024

Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® Mini-Cylinder

Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases (Aasld) 2023 Liver Meeting

Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023

Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection)

Mallinckrodt Reportedly Considers Sale of Opioid Business

Mallinckrodt plc Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

Mallinckrodt plc(OTCPK:MNKT.Q) dropped from S&P TMI Index

NYSE American to Commence Delisting Proceedings Against Mallinckrodt

Mallinckrodt plc Filed for Bankruptcy

Mallinckrodt plc is Heading Towards Bankruptcy

Mallinckrodt plc Contemplates Bankruptcy

Mallinckrodt plc Reaffirms Sales Guidance for the Full-Year 2023

Pomerantz LLP Announces That a Class Action Lawsuit Has Been Filed Against Mallinckrodt plc

Alta Fundamental Requests Mallinckrodt to Convene an Extraordinary General Meeting

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

Mallinckrodt plc Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

Mallinckrodt plc Provides Earnings Guidance for the Year 2023

Mallinckrodt plc to Report Q4, 2022 Results on Feb 28, 2023

Mallinckrodt plc Presents New TERLIVAZ® for Injection Data on Hepatorenal Syndrome Reversal at the Society of Critical Care Medicine 2023 Critical Care Congress

Mallinckrodt plc Announces Appointment of Peter Richardson as Chief Scientific Officer

Mallinckrodt plc Provides Financial Guidance for the Full-Year 2022

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (Hrs) At the American Society of Nephrology (Asn) Kidney Week 2022 Scientific Meeting

Mallinckrodt plc NEW SHS Deleted from OTC Equity

Mallinckrodt plc to Report Q3, 2022 Results on Nov 08, 2022

Mallinckrodt plc Appoints Karen L. Ling as Human Resources and Compensation Committee of the Board

Mallinckrodt plc Appoints Susan Silbermann to Its Board of Directors

Mallinckrodt plc Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System

Mallinckrodt plc Announces Appointment of Lisa French as Executive Vice President and Chief Commercial Officer, Effective October 1, 2022

Mallinckrodt Receives U.S. FDA Approval for Terlivaz (Terlipressin) for Injection for the Treatment of Hepatorenal Syndrome (HRS)

Mallinckrodt plc, Annual General Meeting, Sep 29, 2022

Mallinckrodt plc Provides Update on Executive Committee

Mallinckrodt plc Provides Revenue Guidance for the Full Year of 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd